A Phase Ib Open‑Label, Dose‑Finding Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Avelumab in Combination With M9241(NHS-IL12) in Subjects With Locally Advanced, Unresectable, or Metastatic Solid Tumors

Trial Profile

A Phase Ib Open‑Label, Dose‑Finding Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Avelumab in Combination With M9241(NHS-IL12) in Subjects With Locally Advanced, Unresectable, or Metastatic Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 20 Oct 2017

At a glance

  • Drugs Avelumab (Primary) ; NHS IL12 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Acronyms COMBO
  • Sponsors EMD Serono
  • Most Recent Events

    • 26 Sep 2017 Planned number of patients changed from 140 to 170.
    • 26 Sep 2017 Planned End Date changed from 30 Apr 2018 to 30 Apr 2019.
    • 26 Sep 2017 Planned primary completion date changed from 30 Apr 2018 to 30 Apr 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top